Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

BioAlliance Producing Livatag for New Trial

By Drug Discovery Trends Editor | August 2, 2011

BioAlliance Pharma SA, a company dedicated to specialty and orphan oncology products, announces the initiation of the clinical batches production of Livatag (doxorubicin Transdrug) for its Phase 3 clinical trial in primary liver cancer.

This production will be performed by qualified companies for injectable cytotoxic products in nanoparticle form. The BioAlliance Pharma’s team specialized in industrial development, who previously performed scale up of the technology, will collaborate with its partners throughout the process to ensure the transmission of its know-how specific to nanoparticle Transdrug technology.

The production of clinical trial batches is one of the milestones of Livatag Phase 3 clinical trial in primary liver cancer, last development step of the product.

The Company has enlarged the protection of its Transdrug technology with the grant of a second European patent. This strengthens the industrial property of Livatag and completes the market exclusivity given by the orphan status, thus reinforcing the value of this key asset for the Company.

“The BioAlliance Pharma’s industrial development team and its European partners have been fully committed to prepare the clinical production of Livatag®, relying on their specific nanotechnology expertise and know-how”, declares Judith Greciet, CEO of BioAlliance Pharma.

Date: August 1, 2011
Source: BioAlliance Pharma SA 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50